In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jung Won Shin

Senior Editor

Seoul, South Korea

Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.

Latest From Jung Won Shin

SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal

After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.

Deals Cancer

Q2 Korean Biotech Roundup: Partners Return Multiple Assets

The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.

South Korea Deals

VC-Led Biotech Model Systemically Difficult To Adopt In Korea

A research fellow at South Korea's Science and Technology Policy Institute talked at a recent seminar about the key funding, management and other challenges faced by the domestic biotech sector to sustain growth, and how these contrast with the situation in the US.

South Korea Financing

Asia Deal Watch: ProGen To Partner With Rani On GLP-2 Agonist In Obesity

Plus deals involving Healios/Astellas Institute for Regenerative Medicine, Otsuka/Ionis, IMBiologics/Navigator and more.

Deal Watch Business Strategies

SK Bioscience Snaps Up IDT Biologika To Accelerate Growth

SK Bioscience’s acquisition of top 10 CDMO marks first major acquisition as part of its growth acceleration strategy and the biggest such investment so far by a Korean vaccines firm. Execs say deal is aligned with SK Group’s wider moves to 'rebalance' its businesses.

M & A Manufacturing

SK pharmteco Focusing On BAU Amid BIO 'Buzz', BIOSECURE

SK pharmteco CEO Joerg Ahlgrimm talks to Scrip about the "excitement" at BIO, potential CDMO shifts amid the US BIOSECURE Act, and the Korean CDMO's focus on business as usual as it seeks to diversify and grow.

South Korea United States
See All
UsernamePublicRestriction

Register